Drug Search Results
More Filters [+]

Prednisone

Alternative Names: prednisone, decortin, prednison, lodotra, apo-prednisone, rayos, CORTANCYL, orasone, prednisona, deltasone, cortan, liquid pred, delta-dome, meticorten, paracort, fernisone, servisone, prednicen-m, deltasone 5mg, prednimustine
Latest Update: 2024-11-23
Latest Update Note: Clinical Trial Update

Product Description

Prednisone is a synthetic, anti-inflammatory glucocorticoid that derives from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone is an FDA-approved, delayed-release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases, including immunosuppressive/endocrine, rheumatic, collagen, dermatologic, allergic states, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, acute exacerbations of multiple sclerosis, and as an anti-inflammatory and an antineoplastic agent.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30521230/)

Mechanisms of Action: GR Agonist,Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Intestinal Diseases | Renal Transplant | Transplantation Unspecified | Kidney Diseases

Known Adverse Events: Weight Gain

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Prednisone

Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Latvia, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 85

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Asthma, Allergic|Bronchiolitis Obliterans|Conjunctivitis, Allergic|Diffuse Large B-Cell Lymphoma|Drug Hypersensitivity|Erythema Multiforme|Giant Cell Arteritis|Graft vs Host Disease|Hepatic Insufficiency|Histiocytosis|Hodgkin Lymphoma|Kidney Diseases|Kidney Failure, Chronic|Liver Transplant|Lymphoid Leukemia|Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Multiple Myeloma|Other|Pemphigoid, Bullous|Polymyalgia Rheumatica|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Prostate Cancer|Purpura, Thrombocytopenic, Idiopathic|Pyoderma Gangrenosum|Renal Transplant|Rhinitis, Allergic|T-Cell Peripheral Lymphoma|Thrombocytopenia

Phase 2: Adenocarcinoma|Allogeneic Stem Cell Transplant|COVID-19|Cardiomyopathy, Dilated|Depressive Disorder, Major|Fetal Diseases|Follicular Lymphoma|GM1 Gangliosidosis|Gangliosidoses|Gangliosidosis, GM1|Heart Failure|Idiopathic Pulmonary Fibrosis|Kidney Transplant|Lung Cancer|Nose Cancer|Pneumonia|Pregnancy Complications, Infectious|Pregnancy Outcomes|Radiation Pneumonitis

Phase 1: Acute Myeloid Leukemia|B-Cell Leukemia|Blast Crisis|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PEACE6-Poor Responders

P3

Not yet recruiting

Prostate Cancer

2033-02-01

2024-516905-22-00

P3

Unknown Status

Multiple Myeloma

2031-12-31

CRESCENDO

P3

Recruiting

T-Cell Peripheral Lymphoma

2030-07-01

REFRACT

P2

Recruiting

Follicular Lymphoma

2029-05-31

Recent News Events